Bimekizumab efficacy and safety up to two years in patients with moderate to severe plaque psoriasis switching from ustekinumab: Results from the interim BE BRIGHT open-label extension trial
AUSTRALASIAN JOURNAL OF DERMATOLOGY（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要